Jefferies sees strategic rationale for Genmab sale
Yet another milestone in their partnership adds a new reason for Janssen to swallow its biotech partner Genmab. Jefferies hikes its peak-sales estimate for the two partners’ oncology drug Darzalex by nearly 50%, adding fuel to the acquisition fire.
BY STEFAN SINGH KAILAY
You would be hard pressed to find an analyst or banking firm who are bearish on the potential of the Genmab-developed oncology drug Darzalex, and it is downright impossible to find one who has not raised peak-sales estimates for the drug in the wake of the recent ASH conference in Florida, at which Genmab and Big Pharma partner Janssen presented new data.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Janssen wants more success from Genmab partnership
For abonnenter
CEO: Genmab sustainable, profitable before 2017
For abonnenter
